Company news

Aldeyra Therapeutics, Inc. news in 2022

Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma

December 20, 2022

Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

December 12, 2022

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

November 30, 2022

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

November 28, 2022

Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

November 9, 2022

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

November 2, 2022

Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting

October 25, 2022

Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 5, 2022

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 4, 2022

Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones

September 13, 2022

Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

September 6, 2022

Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights

August 4, 2022

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

July 28, 2022

Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

July 11, 2022

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap

July 10, 2022

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease

June 7, 2022

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

June 6, 2022

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

May 23, 2022

Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 22, 2022

Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness

May 17, 2022

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights

May 4, 2022

Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting

May 3, 2022

Aldeyra Therapeutics Announces Chief Financial Officer Transition

April 27, 2022

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

April 26, 2022

Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 20, 2022

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease

April 4, 2022

Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day

March 28, 2022

Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022

March 21, 2022

Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

March 16, 2022

Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

March 13, 2022

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights

March 9, 2022

Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa

March 7, 2022

Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model

January 31, 2022

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®

January 10, 2022

Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

January 3, 2022

Calls in 2022

Decks in 2022